Prevalence of Clinical and Neuroimaging Markers in Cerebral Amyloid Angiopathy: A Systematic Review and Meta-Analysis.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
06 2022
Historique:
pubmed: 11 3 2022
medline: 26 5 2022
entrez: 10 3 2022
Statut: ppublish

Résumé

Limited data exist regarding the prevalence of clinical and neuroimaging manifestations among patients diagnosed with cerebral amyloid angiopathy (CAA). We sought to determine the prevalence of clinical phenotypes and radiological markers in patients with CAA. Systematic review and meta-analysis of studies including patients with CAA was conducted to primarily assess the prevalence of clinical phenotypes and neuroimaging markers as available in the included studies. Sensitivity analyses were performed based on the (1) retrospective or prospective study design and (2) probable or unspecified CAA status. We pooled the prevalence rates using random-effects models and assessed the heterogeneity using the Cochran We identified 12 prospective and 34 retrospective studies including 7159 patients with CAA. The pooled prevalence rates were cerebral microbleeds (52% [95% CI, 43%-60%]; I Approximately one-half of hospital-based cohort of CAA patients was observed to have cerebral microbleeds, cortical superficial siderosis, mild cognitive impairment, dementia, ICH, or transient focal neurological episodes. Cortical superficial siderosis was the only neuroimaging marker that was associated with higher odds of ICH recurrence. Future population-based studies among well-defined CAA cohorts are warranted to corroborate our findings.

Sections du résumé

BACKGROUND
Limited data exist regarding the prevalence of clinical and neuroimaging manifestations among patients diagnosed with cerebral amyloid angiopathy (CAA). We sought to determine the prevalence of clinical phenotypes and radiological markers in patients with CAA.
METHODS
Systematic review and meta-analysis of studies including patients with CAA was conducted to primarily assess the prevalence of clinical phenotypes and neuroimaging markers as available in the included studies. Sensitivity analyses were performed based on the (1) retrospective or prospective study design and (2) probable or unspecified CAA status. We pooled the prevalence rates using random-effects models and assessed the heterogeneity using the Cochran
RESULTS
We identified 12 prospective and 34 retrospective studies including 7159 patients with CAA. The pooled prevalence rates were cerebral microbleeds (52% [95% CI, 43%-60%]; I
CONCLUSIONS
Approximately one-half of hospital-based cohort of CAA patients was observed to have cerebral microbleeds, cortical superficial siderosis, mild cognitive impairment, dementia, ICH, or transient focal neurological episodes. Cortical superficial siderosis was the only neuroimaging marker that was associated with higher odds of ICH recurrence. Future population-based studies among well-defined CAA cohorts are warranted to corroborate our findings.

Identifiants

pubmed: 35264008
doi: 10.1161/STROKEAHA.121.035836
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1944-1953

Auteurs

Konark Malhotra (K)

Department of Neurology, Allegheny Health Network, Pittsburgh, PA (K.M.).

Aikaterini Theodorou (A)

Second Department of Neurology (A.T., A.H.K., C.Z., G.P.P., G.T.), National and Kapodistrian University of Athens, "Attikon" University Hospital, Greece.

Aristeidis H Katsanos (AH)

Second Department of Neurology (A.T., A.H.K., C.Z., G.P.P., G.T.), National and Kapodistrian University of Athens, "Attikon" University Hospital, Greece.
Department of Neurology, McMaster University/Population Health Research Institute, Hamilton, Canada (A.H.K., A.S.).

Christina Zompola (C)

Second Department of Neurology (A.T., A.H.K., C.Z., G.P.P., G.T.), National and Kapodistrian University of Athens, "Attikon" University Hospital, Greece.

Ashkan Shoamanesh (A)

Department of Neurology, McMaster University/Population Health Research Institute, Hamilton, Canada (A.H.K., A.S.).

Efstathios Boviatsis (E)

Department of Neurosurgery (E.B.), National and Kapodistrian University of Athens, "Attikon" University Hospital, Greece.

George P Paraskevas (GP)

Second Department of Neurology (A.T., A.H.K., C.Z., G.P.P., G.T.), National and Kapodistrian University of Athens, "Attikon" University Hospital, Greece.

Martha Spilioti (M)

First Department of Neurology, AHEPA General Hospital, Aristotle University of Thessaloniki, Greece (M.S.).

Charlotte Cordonnier (C)

University Lille, Inserm, CHU Lille, U1172, LilNCog, Lille Neuroscience and Cognition, France (C.C.).

David J Werring (DJ)

Stroke Research Centre, UCL Queen Square Institute of Neurology, London, United Kingdom (D.J.W.).

Andrei V Alexandrov (AV)

Department of Neurology, University of Tennessee Health Science Center, Memphis (A.V.A., G.T.).

Georgios Tsivgoulis (G)

Second Department of Neurology (A.T., A.H.K., C.Z., G.P.P., G.T.), National and Kapodistrian University of Athens, "Attikon" University Hospital, Greece.
Department of Neurology, University of Tennessee Health Science Center, Memphis (A.V.A., G.T.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH